"Flagellated" cancer cells propel anti-tumor immunity

Abstract

The use of innate immune receptor agonists in cancer therapies has sufered from manydrawbacks. Our recent observations suggest that some of these hurdles can be overcome by introducing fagellin into tumor cells to promote tumor antigen presentation by dendritic cells (dcs) and simultaneously trigger two types of pattern recognition receptors (Prrs). © 2012 Landes Bioscience.